Non - pointing out the risk of investing in DECN and Bozo Berman's tortured past has no bearing on the great work he is doing to save humanity. Comon, do you really think the CEO has time to read message boards? Especially now that he has to assume the role of the sole Board member. The trading of the stock has no bearing on DECN, the money from daily stock trading does not go to DECN or Bozo Berman.
Shouldn't investors be aware;
- of Bozo Berman being sued in the past for exaggerated press releases and hyped up financials
- getting kicked off a stock board spreading rumors of a takeout using an alias name
- all of the past PR that was BS regarding lawsuits, and glucose strip sales
- that DECN is a stinky pinky that has not been audited in 5 years and is a non-SEC reporting company.
I mean, use common sense, Bozo Berman has still not reported he submitted an application to the FDA. His annual report states he still hasn't done trials. Investors still do not know DECN's relationship with the patent? Who owns the patent?
Assuming Bozo Berman is correct and his impedance method is a better mousetrap don't you think DECN's value would be much greater owning the patent than not owning the patent? Who is applying for the application? DECN or the Bio Company of South Korea? What are the terms of the financing, the subscriptions (nothing wrong with selling subscriptions but why did he make investors think this whole 13 mil was nondilutive), and the notes? How many shares are really outstanding fully diluted? If Bozo Berman doesn't take a pay, how is he compensated? Why is Bozo Berman buying equipment for the Korean contractor? Why did Bozo Berman make it appear that DECN employed an R&D team in Korea when he doesn't, aren't they contractors?
The fact is Bozo Berman's DECN traded 8000 shares at a PENNY and a HALF before his first PR that was a CoronaVirus doggy strip announcement. All Bozo Berman had in value for DECN was a failed glucose meter business, operating consistently at twice the cash losses compared to sales. The business model, with only 3 customers for the last 2 years was basically a drop-ship business. Send the meters to Amazon, Walmart or Kimberly Binder and let them fulfill the orders.
Compare that to AYTU, who as a company also treated shareholders badly like many small Bio Techs. At least they had a portfolio of good drugs and hired a national salesforce. They are actually delivering testing kits through a waiver clearance and should generate great cash flow for the 6 months at least. Berman has not even submitted an application yet. He has not done human trials yet and he even admits that because his method is different it will be scrutinized more by the FDA.
I never stated that investors could not make money in Bozo Berman's stock pump schemes. I cautioned investors to be careful. Kind of like musical chairs, make sure you have a seat when the music stops. Well, the music stopped in round 1 at about .25 cents. maybe there will be around 2 but investors are hipper to the risk of investing in these tests. I have owned a few of these companies and think the better longer-term plays will be the real testing capabilities that will be able to pinpoint the L and R strains, and do multiple assays at once. Companies that are more than a one-horse CoVid pony.
Do you really think Bozo Berman is in this for any other reason than to make a buck, and that is fine, but that is Berman's motive?
525 Million meters in 12 months LOL, $4.3 Billion is first year sales. LMFA
He would not have written that if he wasn't in it to just make a buck.
SORRY - BERMAN IS STILL A SCUMBAG
As Ally you to state,
Carry On
News 
Market Data 
Discover 
